Skip to main content

Table 4 Associations between steroid administration and changes in quantitative CT parameters (%) at different stages

From: Usage of compromised lung volume in monitoring steroid therapy on severe COVID-19

Outcome

Stage 2

Stage 3

Stage 4

Stage 5

Changes in quantitative CT parameters (%)

Coefficient

95% CI

P value

Coefficient

95% CI

P value

Coefficient

95% CI

P value

Coefficient

95% CI

P value

Changes in CL a

 − 2.02

 − 4.55 to 0.51

0.12

 − 3.73

 − 7.18 to − 0.29

0.03

 − 3.95

 − 7.57 to − 0.33

0.03

 − 5.01

 − 8.95 to − 1.08

0.01

Changes in NNL b

 − 0.23

 − 1.49 to 1.02

0.71

 − 0.83

 − 2.34 to 0.68

0.28

 − 1.15

 − 2.99 to 0.69

0.22

 − 1.07

 − 3.06 to 0.92

0.28

Changes in PAL c

 − 1.01

 − 2.74 to 0.72

0.25

 − 2.31

 − 4.71 to 0.08

0.06

 − 1.85

 − 4.10 to 0.40

0.11

 − 2.99

 − 5.24 to − 0.75

0.01

Changes in NAL d

3.65

0.68 to 6.63

0.02

8.23

4.50 to 11.96

 < 0.01

7.82

3.41 to 12.23

 < 0.01

9.59

4.65 to 14.53

 < 0.01

Changes in HI e

 − 2.54

 − 5.96 to 0.88

0.14

 − 2.73

 − 6.91 to 1.45

0.20

 − 1.77

 − 7.01 to 3.47

0.50

 − 3.27

 − 8.67to 2.12

0.23

  1. Analyses were performed using linear regression models adjusted for baseline quantitative chest CT parameters. Coefficients represent differences in changes in quantitative CT parameters associated with steroid administration. a Model adjusted for duration and baseline %CL; b Model adjusted for duration and baseline %NNL; c Model adjusted for duration and baseline %PAL; d Model adjusted for duration and baseline %NAL; e Model adjusted for duration and baseline %HI. %CL, percentage of compromised lung volume, calculated as the sum of %PAL and %NNL; %NNL, percentage of nonaerated lung volume; %PAL, percentage of poorly aerated lung volume; %NAL, percentage of normally aerated lung volume; %HI, percentage of hyperinflated lung volume